Iveric Bio Inc Expected To Post A Loss Of 37 Cents A Share: Earnings Preview

IVERIC bio

27/02/2023 14:44

* IVERIC bio Inc  ISEE.OQ   ISEE.O  is expected to show no
change
in quarterly revenue when it reports  results on March 1. 
    * 
    * ​Refinitiv's mean analyst estimate for IVERIC bio Inc is
for a
loss of 37 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for IVERIC bio
Inc is
$30.5​, above​ its last closing price of $20.71. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.42       -0.40      -0.35     Beat    13.4
 Jun. 30 2022  -0.31       -0.31      -0.41     Missed  -30.4
 Mar. 31 2022  -0.29       -0.29      -0.29     Met     1.1​
 Dec. 31 2021  -0.24       -0.25      -0.29     Missed  -18.2
 ​​Sep.        -0.29       -0.29      -0.23     Beat    20.1
 30 2021                                                
 Jun. 30 2021  -0.26       -0.26      -0.32     Missed  -22.8​
 Mar. 31 2021  -0.25       -0.25      -0.29     Missed  -16.5
 Dec. 31 2020              -0.26      -0.27     Missed  -5.5
 This summary was machine generated February 27 at 14:44 GMT. 
All figures in US dollars  unless otherwise stated